Navigation Links
Bacteria adapt and evade nanosilver's sting -- new study
Date:5/8/2013

s should take into consideration the potential for longer-term adverse outcomes," says Gunawan.

The researchers say these adverse impacts could be more pronounced given the near-ubiquitous nature of the Bacillus bacteria, which originate from airborne spores, and because the resistance trait can potentially be transferred to the genes of other micro-organisms.

"For the medical use of nanosilver, this implies the potential for reduced efficacy and the development of resistant populations in clinical settings," says co-author Dr Christopher Marquis, a senior lecturer from the UNSW School of Biotechnology and Biomolecular Sciences.

"This work suggests caution in the widespread use of nanosilver and the requirement for much deeper research into the antimicrobial mechanisms, the extent of adaptability and the molecular basis or genetics of cell defence against the antimicrobial activity."


'/>"/>

Contact: Myles Gough
myles.gough@unsw.edu.au
61-293-851-933
University of New South Wales
Source:Eurekalert

Page: 1 2

Related biology news :

1. Leading evolutionary scientist to discuss how genome of bacteria has evolved
2. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
3. Team discovers how bacteria resist a Trojan horse antibiotic
4. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
5. Bacterial shock to recapture essential phosphate
6. Disarming disease-causing bacteria
7. Study shows unified process of evolution in bacteria and sexual eukaryotes
8. Invisible helpers: How probiotic bacteria protect against inflammatory bowel diseases
9. Researchers develop rapid test strips for bacterial contamination in swimming water
10. Bacteria discovery could lead to antibiotics alternatives
11. Agricultural bacteria: Blowing in the wind
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... major interest in neuroscience. A large number of ... of Wallerian degeneration: transcription factor activation, immune response, ... responses in the distal segment of the sciatic ... in gene expression between the proximal and distal ... from Nantong University, China used microarrays to analyze ...
(Date:7/30/2014)... robust therapies for spinal cord injury (SCI), traumatic brain ... A great deal has been learned over the past ... environmental factors that regulate axon growth, but this large ... available therapeutics. Prof. Lemmon and his team from University ... many root causes, but a consensus is emerging that ...
(Date:7/30/2014)... roughly 3,000 pieces is still in its infant stage. ... be of major significance. "Amazingly often, we are findingin ... amber that we found in Baltic amber," explained Bonn ... amber comes from the Baltic Sea region, which is ... are, e.g., the coastal regions of Mecklenburg, Poland and ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2
... with the heat insulation of leaf litter and soil can ... helping land managers find the best time to use prescribed ... "Acorns inside the leaf litter or in the soil ... Greenberg, Forest Service Southern Research Station (SRS) researcher and lead ...
... Ore. Climate change, habitat destruction, pollution and invasive ... amphibian declines and extinctions, researchers suggest in a new ... in the form of infectious disease. Amphibians are ... range of infectious organisms, including viruses, bacteria and fungi, ...
... from the University of Southampton, which examines how dolphins might ... man-made sonar to detect targets, such as sea mines, in ... to blow ,bubble nets, around schools of fish, which force ... dolphins to pick off. However, such bubble nets would confound ...
Cached Biology News:Leaf litter and soil protect acorns from prescribed fire 2Environmental concerns increasing infectious disease in amphibians, other animals 2Do dolphins think nonlinearly? 2Do dolphins think nonlinearly? 3
(Date:7/30/2014)... Wellesley, MA (PRWEB) July 30, 2014 ... report, Global Markets for Enzymes in Industrial Applications ... to reach to nearly $7.1 billion by 2018, registering ... Maximum growth is estimated to be recorded in the ... the forecast period. , Enzyme technology has influenced almost ...
(Date:7/30/2014)... Md. , July 30, 2014 ... components to interrogate biology, but such devices can ... As such, researchers have looked ... in vitro metabolic engineering to characterize ... a chip. New devices are envisioned to recreate ...
(Date:7/30/2014)... July 30, 2014 Connecticut Center for ... based in East Hartford, Conn., was awarded a Rural ... of a project that will determine the feasibility of ... north-central Connecticut. USDA Rural Development provided $53,000 for CCAT ... the second phase of the feasibility study in fiscal ...
(Date:7/29/2014)... 30, 2014 SoundConnect , ... company, is proud to announce the strategic additions ... in their Boston, Charleston and Atlanta offices. ... increased demand for hosted solutions, collaboration and mobility ... reduce cost. , SoundConnect was founded in 2004, ...
Breaking Biology Technology:Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3SoundConnect Organization and Culture is Evolving 2
... LAIYANG, China, Feb. 17 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. ... pharmaceutical company with its principal operations in the,People,s Republic ... quarter of its fiscal year 2009 ended December 31, ... Fiscal Year 2009 Highlights, -- Revenue ...
... in the Biotech IndustryFT. LAUDERDALE, Fla., Feb. ... full-service securities broker-dealer and investment bank, is ... Newbridge BioVentures Division ("NBV"). NBV is dedicated ... biotech industry and related investment opportunities for ...
... 17 Human Genome Sciences, Inc. (Nasdaq: ... GSK ) has initiated a Phase 3 clinical trial ... Syncria (R) (albiglutide) in the long-term treatment of ... will receive a $9 million milestone payment in the ...
Cached Biology Technology:Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16Newbridge Securities Corporation Forms BioVentures Division 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 4
Human Serpin B5/Maspin Affinity Purified Polyclonal Ab...
... S.J. Allen (1995) This book ... authorities on current issues relating to the ... major advances have been made recently which ... Topics include molecular neuropathology through clinical and ...
Normal human serum, single donor...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Biology Products: